Cervical cancer is a leading cause of death among women in the developing world. Conventional cytology-based cervical cancer screening programs have been largely ineffectual at reducing the cervical cancer burden in low-resource settings. In response, alternative strategies have been tested, such as visual inspection with acetic acid (VIA) screening and human papillomavirus (HPV) DNA-based test...

BACKGROUND Knowledge of prevalence rates and distribution of human papillomavirus (HPV) genotypes prior high HPV vaccine coverage is necessary to assess its expected impact on HPV ecology and on cervical lesions and cancers. METHODS Residual specimens of cervical cytology (N = 6,538) were obtained from 16 sites participating in organised cervical cancer screening pilot programs throughout Fra...

Scientific understanding of the role of HPV in cervical cancer increased dramatically through the 1990s. The last seven years have seen the introduction of HPV vaccination for young women in many developed countries. In parallel, the potential for HPV testing to improve current cervical screening practices is being explored. Primary HPV testing in the cervical screening context involves testing...

OBJECTIVE To estimate the annual cost of the National Cervical Cancer Screening Program (CCSP) of the Mexican Institute of Social Security (IMSS). MATERIALS AND METHODS This cost analysis examined regional coverage rates reported by IMSS. We estimated the number of cytology, colposcopy, biopsy and pathology evaluations, as well as the diagnostic test and treatment costs for cervical intraepit...

To assess the utility of makorin ring finger protein 1 (MKRN1) as a marker of cervical pathology.A PROspective specimen collection and retrospective Blinded Evaluation study was conducted. Liquid-based cytology samples were collected from 187 women, embedding all residuals as cell blocks for immunohistochemical staining of MKRN1 and P16 . Results of liquid-based cervical cytology, immunostained...

Background: Conventional cervical cytology is the most widely used cervical cancer screening test in the world. Squamous intraepithelial neoplasia (SIL) and cervical cancer remain important health problems for women worldwide. Aim and Objective: To study various types of cervical lesions with relevant factors such as age, parity, to classify cervical lesions into malignant & benign groups and t...

BACKGROUND Vaginal self-sampling for human papillomavirus (HPV) DNA testing could increase rates of screening participation. In clinic-based settings, vaginal HPV testing is at least as sensitive as cytology for detecting cervical intraepithelial neoplasia (CIN) grade 2 or worse; however, effectiveness in home settings is unknown. We aimed to establish the relative sensitivity and positive pred...

Since the Cervical Screening Programme was introduced in England, the incidence of cervical cancer has fallen by 44% and number of deaths from the disease by 70% (fig 1⇓). This effect has also been seen in other countries. 2 The discovery of human papillomavirus (HPV)DNA in cervical cancer and in subsequent molecular biology and epidemiological studies shows that persistent cervical infection w...

New commercially available Human Papillomavirus (HPV) assays need to be evaluated in a variety of cervical screening settings. Cobas HPV Test (cobas) is a real-time PCR-based assay allowing for separate detection of HPV genotypes 16 and 18 and a bulk of 12 other high-risk genotypes. The aim of the present study, Horizon, was to assess the prevalence of high-risk HPV infections in an area with a...

In 2009, the Cytopathology Education and Technology Consortium issued a statement on human papillomavirus (HPV) DNA test utilization that was published in multiple journals. 1 This statement was a concise summary of the clinical indications for high-risk or oncogenic HPV testing based on guidelines from the American Society for Colposcopy and Cervical Pathology (ASCCP) and the American Cancer S...